This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. In 2015, reported funding for HIV prevention R&D decreased from US$ 1.25 billion in 2014 to US$1.20 billion. However, overall funding has remained essentially flat for over a decade. While investments towards research for preventive vaccines and female condoms increased from 2014 levels, investments towards microbicides, PrEP, TasP, VMMC and PMTCT declined.
HIV Prevention Research & Development Investments, 2000–2015: Investment priorities to fund innovation in a challenging global health landscape
HIV Prevention Research & Development Investments, 2000–2015: Investment priorities to fund innovation in a challenging global health landscape (1-pager)
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. In 2015, reported funding for HIV prevention R&D decreased from US$ 1.25 billion in 2014 to US$1.20 billion. However, overall funding has remained essentially flat for over a decade. While investments towards research for preventive vaccines and female condoms increased from 2014 levels, investments towards microbicides, PrEP, TasP, VMMC and PMTCT declined.
Trial Participants by Prevention Research Area, 2015
Given the higher rates of acquisition seen across so-called key populations—members of highly burdened and underserved groups—it is critical to provide access to the research process such that they can participate and reap more immediate benefit of scientific progress. Greater efforts must be made to include key populations in this crucial process for the HIV prevention response to be truly impactful.
Global HIV Prevention R&D Investments by Technology, 2000-2015
In 2015, global funding for HIV prevention R&D declined slightly, from US $1.25 billion in 2014 to US $1.20 billion in 2015. This continues a decade of roughly flat funding. The US public sector remained the largest global contributor at US $850 million, and together with the Bill & Melinda Gates Foundation, the largest philanthropic funder, constituted 81 percent of all funding.
MPT Product Development: Many possibilities for MPT development
This table shows the indication (prevention effect the product is designed to have—e.g., pregnancy or one or more STIs) the way it will be delivered (e.g., through vaginal gel, pill or injection), how it might work to provide preventive effect (for example, as a physical barrier to prevent fluid exchange or as a hormonal contraceptive) and what kind of dosage could be possible (e.g., daily pill or application, sustained through the blood or around sex).
Excerpted from the MPTs factsheet.
New Analysis on Hormonal Contraception and HIV: WHO and others must act
An update excerpted from AVAC Report 2016: Big Data, Real People.
Durban 2016 Scorecard—How did it deliver?
Excerpted from Px Wire, this is a scorecard for the 2016 International AIDS Conference. Did it deliver?
ARV-Based Prevention Pipeline
The pipeline of ARV-based prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable ARVs. Not pictured are a range of multipurpose technologies in development that aim to reduce women’s risk of HIV and STIs, and provide effective contraception.
State of the Funding in 2015
In 2015, preliminary reported funding for HIV prevention R&D decreased from US$ 1.25 billion in 2014 to US$1.18 billion. However, overall funding has remained essentially flat for over a decade. While investments towards research for preventive vaccines and female condoms increased from 2014 levels, investments towards microbicides, PrEP, TasP, VMMC, declined. Prevention of vertical transmission remained almost flat-funded in 2015.
The US public sector remained the single largest source of funding for HIV prevention R&D, with a total investment of US$836 million. European public sector investment continued its decade-long decline, falling US$8 million from 2014. Public sector funding outside the US and Europe also continued to fall, decreasing another US$5 million in 2015 for a total US$18 million decline since 2013. Finally, the philanthropic sector comprised 13% of all funding at US$155 million, a 23 percent decrease from 2014 contributions, while the commercial sector increased its contribution to HIV prevention R&D by 19 percent over 2014.
AVAC Report 2016: Big Data, Real People
In the Report, we argue that the state of HIV prevention data collection in 2016 is poor. One part of the solution lies in the adoption of “HIV Prevention Data Dashboards”. This tracking tool could bring the same specificity and accountability to non-ART prevention services that the “treatment cascade” of diagnosis, initiation, retention and virologic suppression does for antiretrovirals for people living with HIV.